LONDON, April 25, 2017 /PRNewswire/ --
PharmaBoardroom today releases its new 42-page Healthcare &
Life Sciences Review Greece 2017.
This report offers companies, investors, policymakers, and
stakeholders crucial insight into Greece; a country with an admirable and
long-standing history in healthcare and pharmaceuticals, but one
that is still struggling to find its way out of a national debt
crisis. The interviewees from government, associations, MNCs and
local players featured in the report discuss the various issues and
barriers to growth created by economic austerity policies, but also
how innovative and quick-thinking players have found opportunity in
crisis and are adapting to the new reality.
The report features in-depth exclusive interviews with leading
figures from public institutions and private companies,
comprehensive articles, and up-to-date facts and figures on
Greece's macroeconomic situation,
as well as its healthcare and pharma sectors.
Features
Featured topics include:
- Reimbursement
- Market Access
- Generics Penetration
- Cuts and Clawbacks
- Clinical Trials
- Pharma Logistics
Interviews
The report features in-depth interviews with:
- Bersimis Sotirios, EOPYY
- Mihalis Himonas, SFEE
- Theodore Tryfon, PEF
- Vassilios Katsos,
Pharmathen
- Sophia ROmboli &
Konstantinos Karakostas,
ZeinCRO
- John Kandylis, Olympias Logistics
- John Bouros, Alvion
- Evi Christofilopoulou, MP for Labour, Social Insurance and
Health
Quotes
"It is important to recognize the extent to which the Greek
market has been disfigured by the country's financial and banking
woes. Prior to the crisis, Greek pharma could legitimately claim to
be the sixth largest market in Europe" - Christos
Dakas, Shire
"The government's commitment to capping the public pharma budget
to one percent of GDP is absolutely nonsensical… that particular
metric only works when a country's GDP is at its peak and stable,
and enjoys the potential for growth" - Harry
Nardis, Astellas
"In every civilized country, the trend has been for healthcare
and pharmaceutical expenditure to increase every year as costlier,
new generation sophisticated products enter the market. This
regressive trend is thus clearly unsustainable." - Philippe Lambrinos, Pierre Fabre
"Regardless of the challenges posed by the financial squeeze,
most actors are perceptive of the underlying potential of this
important market and acknowledge that there are no shortages of
patients with inelastic needs that need responding to" -
Konstantinos Kofinas,
Merck
Click here to register and download the report.
SOURCE PharmaBoardroom